Company Description
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2021 |
| IPO Date | May 8, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Gary Glick |
Contact Details
Address: 51 Sleeper Street, Suite 800 Boston, Massachusetts 02210 United States | |
| Phone | 617 865 9628 |
| Website | odysseytx.com |
Stock Details
| Ticker Symbol | ODTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1882782 |
| CUSIP Number | 67613T104 |
| ISIN Number | US67613T1043 |
| Employer ID | 86-3384382 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gary D. Glick, Ph.D. | President, Chief Executive Officer and Director |
| Julie Clauss | Chief Operating Officer |
| Jason Haas | Chief Financial Officer |
| William Roush, Ph.D. | Executive Vice President, Head of Small Molecule Research |
| Kira M. Schwartz | Executive Vice President, General Counsel and Secretary |
| Stephen Soisson, Ph.D. | Executive Vice President, Protein Therapeutics and Structural Biology |
| Collin Todd | Senior Vice President, Strategy and Business Development |
| Jeffrey M. Leiden, M.D., Ph.D. | Chair and Director |
| Charles Baum, M.D., Ph.D. | Director |
| Jill Carroll | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 18, 2026 | SCHEDULE 13D | Filing |
| May 15, 2026 | SCHEDULE 13D | Filing |
| May 15, 2026 | SCHEDULE 13D | Filing |
| May 11, 2026 | 8-K | Current Report |
| May 11, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 8, 2026 | 424B4 | Prospectus |
| May 7, 2026 | EFFECT | Notice of Effectiveness |
| May 7, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| May 7, 2026 | CERT | Certification by an exchange approving securities for listing |
| May 5, 2026 | 8-A12B | Registration of securities |